Cargando…

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis

BACKGROUND: Anti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of patients. ICI-treated patients develop unique toxicities - immune related adverse events (irAEs) – that arise from unrestrained immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bastacky, Melissa L., Wang, Hong, Fortman, Dylan, Rahman, Zahra, Mascara, Gerard P., Brenner, Timothy, Najjar, Yana G., Luke, Jason J., Kirkwood, John M., Zarour, Hassane M., Davar, Diwakar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662734/ https://www.ncbi.nlm.nih.gov/pubmed/34900695 http://dx.doi.org/10.3389/fonc.2021.749064

Ejemplares similares

A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
por: Fortman, Dylan, et al.
Publicado: (2023)

Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
por: Davar, Diwakar, et al.
Publicado: (2022)

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
por: Augustin, Ryan C, et al.
Publicado: (2023)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
por: Davar, Diwakar, et al.
Publicado: (2015)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8(+) T cell dysfunction in melanoma patients
por: Fourcade, Julien, et al.
Publicado: (2010)

Targeting multiple inhibitory receptors to reverse melanoma-induced T cell dysfunction
por: Zarour, Hassane M
Publicado: (2015)

Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study
por: Augustin, Ryan C., et al.
Publicado: (2023)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
por: Ribas, Antoni, et al.
Publicado: (2021)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes
por: Karapetyan, Lilit, et al.
Publicado: (2023)

Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?
por: Najjar, Yana G
Publicado: (2021)

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2015)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
por: Valentin, Julie, et al.
Publicado: (2021)

In memoriam: Soldano Ferrone, MD, PhD (1940–2023)
por: Whiteside, Theresa, et al.
Publicado: (2023)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
por: Garcia, Christine A., et al.
Publicado: (2018)

Targeting GITR in cancer immunotherapy – there is no perfect knowledge
por: Davar, Diwakar, et al.
Publicado: (2023)

Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
por: Dawidowska, Anna, et al.
Publicado: (2022)

Absence of γ-Interferon–inducible Lysosomal Thiol Reductase in Melanomas Disrupts T Cell Recognition of Select Immunodominant Epitopes
por: Haque, M. Azizul, et al.
Publicado: (2002)

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
por: Luke, Jason J., et al.
Publicado: (2015)

The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019
por: Ascierto, Paolo A., et al.
Publicado: (2020)

The impact of ejaculatory dysfunction upon the sufferer and his partner
por: Abdo, Carmita Helena Najjar
Publicado: (2016)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma
por: Zhao, Jing-Jing, et al.
Publicado: (2020)

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
por: Najjar, Yana G., et al.
Publicado: (2017)

Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000)

Aggressive Stereotactic Radiosurgery Coupled With Immune and Targeted Therapy for Recurrent Melanoma Brain Metastases: A Case Report and Literature Review
por: Wei, Zhishuo, et al.
Publicado: (2022)

Metastatic Melanoma With Sebocyte-Like Melanocytes and Widespread Visceral Involvement
por: Chang, Li-Wei, et al.
Publicado: (2020)

Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients
por: Eikenes, Grethe, et al.
Publicado: (2023)

Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)
por: Ascierto, Paolo A., et al.
Publicado: (2020)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Yellow color upon dermatoscopy does not exclude melanoma!
por: Longo, Caterina, et al.
Publicado: (2014)

Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada
por: O’Sullivan, Dylan E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nkjeo5sbcag7pm30fjeu1beu2k